

P=.002

-0009

2000

4000

 3 [H]-THYMIDINE INCORPORATION

3000

2000-

1000

SPLEEN(S): SPLEEN CELLS FROM RATS TREATED WITH SALINE WHEN THEY WERE FETUSES.

HEP: IRRADIATED HUMAN HEPATOCYES.

SPLEEN(IU): SPLEEN CELLS FROM RATS TOLERIZED BY INTRAUTERINE INJECTION OF HUMAN HEPATOCYTE LYSATES.

SPLEEN(IU/IS): SPLEEN CELLS FROM RAT TOLERIZED BY INTRAUTERINE INJECTION OF HUMAN HEPATOCYTE LYSATES FOLLOWED BY INTRASPLENIC TRANSPLANTATION OF HUMAN HEPATOCYTES AFTER BIRTH.

HEP ALONE

SPLEEN(IU/IS)+HEP

SPLEEN(IU)+HEP


2PLEEN(S)+HEP


SPLEEN(S)+SPLEEN


SPLEEN(S) ALONE

1 2 3 4 5

FIG.2











FIG.5



1 2 3 4 5 6 7 68,000 - -

10 ng standard human albumin 10 ng standard rat albumin 2 days 2 weeks

3:

4:


5: 3 weeks


5 weeks 6:

7: 6 weeks

FIG.7

Time course of human albumin and HBV expression








FIG.8F

Anti Human Albumin




FIG.9A

Anti Hepatitis B Surface Antigen



FIG.9B

Rat CA3 Hepatocytes alone

Rat CA2

Hepatocytes Plus HBV



FIG.9C





FIG.9D



RT-PCR Human Albuman mRNA

10 11 2 3 8 9



- 1000 bp ladder 1:
- 2: Rat RNA
- 3: Human RNA
- HepG2.2.15 RNA
- Rat CA1 Human hepatocytes + HBV
- Rat CA2 Human hepatocytes + HBV Rat CA3 Human hepatocytes 6:
- 7:
- Rat CA4 Human hepatocytes 8:
- Rat CA5 HBV 9:
- 10: Rat CA6 HBV
- 11: Rat CA7 Saline

FIG.10

RT-PCR Human Albumin RNA





FIG.11A

RT-PCR HBV RNA



- 1: 1 kbp ladder
- 2: Rat liver RNA
- 3: Human liver RNA
- 4: HepG2.2.15 RNA
- 5: Rat CA2 Human hepatocytes + HBV, 1 week post
- 6: Rat CA2 6 weeks post
- 7: Rat CA2 14 weeks post

FIG.11B




FIG.12

Hepatocytes plus HBV

1 week




FIG.13A

Hepatocytes plus HBV

6 weeks




FIG.13B

Hepatocytes plus HBV

14 weeks




FIG.13C

Hepatocytes plus HBV

1 week




FIG.14A

Hepatocytes plus HBV

6 weeks




FIG.14B

Hepatocytes plus HBV

14 weeks




FIG.14C






FIG.16A




FIG.16B




FIG.16C




FIG.16D




FIG.16E




FIG.16F



FIG.17A




FIG.17B




FIG.17C




FIG.17D











FIG.18B














F16.22



Stimulator Cells








FIG. 25

FIG. 26A

Primary human hepatocytes


6 wks 16 wks


Tolerized and transplanted


Tolerized but not transplanted



FIG. 26B palb3 plasmid











FIG. 28

FIG. 29 E

human Albumin **BrdU** Tolerized with T3 no transplantation FIG. 29A FIG. 29B **Tolerized** with T3 and transplantation FIG. 29C FIG. 29D **Control** no T3 no trans-

FIG. 29 F

plantation



161 nt

100 fg 10 fg 1 fg 0.1 fg 100 bp ladder

F16.30

		Time F	Time Post-HCV Inoculation (weeks)	ılation (weeks)		
	2	4	9	∞	12	16
Huh7	+	+	+	+	+	+
HepG2	+		. 1			FIG
РНН	+	+	•	1		31
PBS	+		•			

F16.32

